Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS FEATURE

US could soon approve MDMA therapy — opening an era of psychedelic medicine

Perceptions have shifted dramatically in the past few years on the therapeutic value of illicit drugs such as ecstasy. But questions still linger about what FDA approval might look like.
  1. Sara Reardon

    1. Sara Reardon is a freelance journalist based in Bozeman, Montana.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Animated illustration that shows a person with PTSD being lifted by the effects of MDMA in therapy.

Illustration by Adrià Voltà

For Rick Doblin, 2023 could be a landmark year: the year that the US government decides whether it will allow the use of hallucinogenic drugs to treat mental illness.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 616, 428-430 (2023)

doi: https://doi.org/10.1038/d41586-023-01296-3

References

  1. Mitchell, J. M. et al. Nature Med. 27, 1025–1033 (2021).

    Article  PubMed  Google Scholar 

  2. Vesentini, L. et al. Arch. Sex. Behav. 51, 453–463 (2022).

    Article  PubMed  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links